155 related articles for article (PubMed ID: 29420662)
1. Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers.
Borek A; Sokolowska-Wedzina A; Chodaczek G; Otlewski J
PLoS One; 2018; 13(2):e0192194. PubMed ID: 29420662
[TBL] [Abstract][Full Text] [Related]
2. High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer.
Sokolowska-Wedzina A; Chodaczek G; Chudzian J; Borek A; Zakrzewska M; Otlewski J
Mol Cancer Res; 2017 Aug; 15(8):1040-1050. PubMed ID: 28483948
[TBL] [Abstract][Full Text] [Related]
3. Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity.
Chudzian J; Szlachcic A; Zakrzewska M; Czub M; Pustula M; Holak TA; Otlewski J
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30134556
[TBL] [Abstract][Full Text] [Related]
4. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
[TBL] [Abstract][Full Text] [Related]
5. Phage antibody library screening for the selection of novel high-affinity human single-chain variable fragment against gastrin receptor: an in silico and in vitro study.
Jalilzadeh-Razin S; Mantegi M; Tohidkia MR; Pazhang Y; Pourseif MM; Barar J; Omidi Y
Daru; 2019 Jun; 27(1):21-34. PubMed ID: 30607886
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Sommer A; Kopitz C; Schatz CA; Nising CF; Mahlert C; Lerchen HG; Stelte-Ludwig B; Hammer S; Greven S; Schuhmacher J; Braun M; Zierz R; Wittemer-Rump S; Harrenga A; Dittmer F; Reetz F; Apeler H; Jautelat R; Huynh H; Ziegelbauer K; Kreft B
Cancer Res; 2016 Nov; 76(21):6331-6339. PubMed ID: 27543601
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44.
Diebolder P; Mpoy C; Scott J; Huynh TT; Fields R; Spitzer D; Bandara N; Rogers BE
J Nucl Med; 2021 Jan; 62(1):137-143. PubMed ID: 32513906
[TBL] [Abstract][Full Text] [Related]
8. Phage display-based on-slide selection of tumor-specific antibodies on formalin-fixed paraffin-embedded human tissue biopsies.
Ten Haaf A; Pscherer S; Fries K; Barth S; Gattenlöhner S; Tur MK
Immunol Lett; 2015 Aug; 166(2):65-78. PubMed ID: 26045318
[TBL] [Abstract][Full Text] [Related]
9. The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
Poźniak M; Porębska N; Krzyścik MA; Sokołowska-Wędzina A; Jastrzębski K; Sochacka M; Szymczyk J; Zakrzewska M; Otlewski J; Opaliński Ł
Mol Med; 2021 May; 27(1):46. PubMed ID: 33962559
[TBL] [Abstract][Full Text] [Related]
10. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
[TBL] [Abstract][Full Text] [Related]
11. Selection of potential therapeutic human single-chain Fv antibodies against cholecystokinin-B/gastrin receptor by phage display technology.
Tohidkia MR; Asadi F; Barar J; Omidi Y
BioDrugs; 2013 Feb; 27(1):55-67. PubMed ID: 23344946
[TBL] [Abstract][Full Text] [Related]
12. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
[TBL] [Abstract][Full Text] [Related]
13. Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor.
Nickho H; Younesi V; Aghebati-Maleki L; Motallebnezhad M; Majidi Zolbanin J; Movassagh Pour A; Yousefi M
Bioengineered; 2017 Sep; 8(5):501-510. PubMed ID: 27849134
[TBL] [Abstract][Full Text] [Related]
14. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
15.
Carter JH; Cottrell CE; McNulty SN; Vigh-Conrad KA; Lamp S; Heusel JW; Duncavage EJ
Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 28835367
[No Abstract] [Full Text] [Related]
16. Reformatting of scFv antibodies into the scFv-Fc format and their downstream purification.
Bujak E; Matasci M; Neri D; Wulhfard S
Methods Mol Biol; 2014; 1131():315-34. PubMed ID: 24515475
[TBL] [Abstract][Full Text] [Related]
17. Shelf-Life Extension of Fc-Fused Single Chain Fragment Variable Antibodies by Lyophilization.
Schneider KT; Kirmann T; Wenzel EV; Grosch JH; Polten S; Meier D; Becker M; Matejtschuk P; Hust M; Russo G; Dübel S
Front Cell Infect Microbiol; 2021; 11():717689. PubMed ID: 34869052
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
19. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
20. Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen.
Zhang JL; Gou JJ; Zhang ZY; Jing YX; Zhang L; Guo R; Yan P; Cheng NL; Niu B; Xie J
Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):237-41. PubMed ID: 16698583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
